Year |
Citation |
Score |
2020 |
Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nature Reviews. Neuroscience. PMID 32929261 DOI: 10.1038/S41583-020-0367-2 |
0.335 |
|
2020 |
Duerler P, Schilbach L, Stämpfli P, Vollenweider FX, Preller KH. LSD-induced increases in social adaptation to opinions similar to one's own are associated with stimulation of serotonin receptors. Scientific Reports. 10: 12181. PMID 32699231 DOI: 10.1038/S41598-020-68899-Y |
0.333 |
|
2020 |
Weber LA, Diaconescu AO, Mathys C, Schmidt A, Kometer M, Vollenweider F, Stephan KE. Ketamine Affects Prediction Errors about Statistical Regularities: A Computational Single-Trial Analysis of the Mismatch Negativity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 32561673 DOI: 10.1523/Jneurosci.3069-19.2020 |
0.386 |
|
2020 |
Lewis CR, Preller KH, Braden BB, Riecken C, Vollenweider FX. Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience. Biomedicines. 8. PMID 32085521 DOI: 10.3390/Biomedicines8020034 |
0.382 |
|
2019 |
Smigielski L, Kometer M, Scheidegger M, Krähenmann R, Huber T, Vollenweider FX. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Scientific Reports. 9: 14914. PMID 31649304 DOI: 10.1038/S41598-019-50612-3 |
0.302 |
|
2019 |
Pokorny T, Duerler P, Seifritz E, Vollenweider FX, Preller KH. LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making. Psychological Medicine. 1-10. PMID 31500679 DOI: 10.1017/S0033291719002393 |
0.333 |
|
2019 |
Dornbierer DA, Kometer M, Von Rotz R, Studerus E, Gertsch J, Gachet MS, Vollenweider FX, Seifritz E, Bosch OG, Quednow BB. Effects of gamma-hydroxybutyrate on neurophysiological correlates of performance and conflict monitoring. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 30824339 DOI: 10.1016/J.Euroneuro.2019.02.004 |
0.313 |
|
2019 |
Preller KH, Razi A, Zeidman P, Stämpfli P, Friston KJ, Vollenweider FX. Effective connectivity changes in LSD-induced altered states of consciousness in humans. Proceedings of the National Academy of Sciences of the United States of America. PMID 30692255 DOI: 10.1073/Pnas.1815129116 |
0.378 |
|
2019 |
Moujaes F, Preller K, Vollenweider F, Schleifer C, Ji JL, Adkinson B, Kolobaric A, Flynn M, Fineberg S, Krystal J, Repovs G, Santamauro N, Morgan P, Savic A, Cho Y, et al. S159. NMDA Receptor Antagonism Effects on Delayed Spatial Working Memory and Distraction in Comparison With Schizophrenia Biological Psychiatry. 85: S358. DOI: 10.1016/J.Biopsych.2019.03.910 |
0.322 |
|
2018 |
Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, Stämpfli P, Seifritz E, Repovs G, Krystal JH, Murray JD, Vollenweider FX, Anticevic A. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife. 7. PMID 30355445 DOI: 10.7554/Elife.35082 |
0.378 |
|
2018 |
Preller KH, Schilbach L, Pokorny T, Flemming J, Seifritz E, Vollenweider FX. Role of the 5-HTreceptor in self- and other-initiated social interaction in LSD-induced states - a pharmacological fMRI study. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 29555857 DOI: 10.1523/Jneurosci.1939-17.2018 |
0.328 |
|
2018 |
Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, Stämpfli P, Seifritz E, Repovs G, Krystal JH, Murray JD, Vollenweider FX, Anticevic A. Author response: Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor Elife. DOI: 10.7554/Elife.35082.028 |
0.302 |
|
2017 |
Kraehenmann R, Pokorny D, Aicher H, Preller KH, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX. LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation. Frontiers in Pharmacology. 8: 814. PMID 29167644 DOI: 10.3389/Fphar.2017.00814 |
0.383 |
|
2017 |
Barrett FS, Preller KH, Herdener M, Janata P, Vollenweider FX. Serotonin 2A Receptor Signaling Underlies LSD-induced Alteration of the Neural Response to Dynamic Changes in Music. Cerebral Cortex (New York, N.Y. : 1991). 1-12. PMID 29028939 DOI: 10.1093/Cercor/Bhx257 |
0.359 |
|
2017 |
Lewis CR, Preller KH, Kraehenmann R, Michels L, Stämpfli P, Vollenweider FX. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. Neuroimage. PMID 28711736 DOI: 10.1016/J.Neuroimage.2017.07.020 |
0.342 |
|
2017 |
Pokorny T, Preller KH, Kometer M, Dziobek I, Vollenweider FX. Effect of psilocybin on empathy and moral decision-making. The International Journal of Neuropsychopharmacology. PMID 28637246 DOI: 10.1093/Ijnp/Pyx047 |
0.333 |
|
2017 |
Kraehenmann R, Pokorny D, Vollenweider L, Preller KH, Pokorny T, Seifritz E, Vollenweider FX. Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology. PMID 28386699 DOI: 10.1007/S00213-017-4610-0 |
0.372 |
|
2017 |
Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, Liechti ME, Seifritz E, Vollenweider FX. The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation. Current Biology : Cb. PMID 28132813 DOI: 10.1016/J.Cub.2016.12.030 |
0.392 |
|
2016 |
Preller KH, Vollenweider FX. Phenomenology, Structure, and Dynamic of Psychedelic States. Current Topics in Behavioral Neurosciences. PMID 28025814 DOI: 10.1007/7854_2016_459 |
0.302 |
|
2016 |
Kometer M, Vollenweider FX. Serotonergic Hallucinogen-Induced Visual Perceptual Alterations. Current Topics in Behavioral Neurosciences. PMID 27900674 DOI: 10.1007/7854_2016_461 |
0.318 |
|
2016 |
Preller KH, Pokorny T, Hock A, Kraehenmann R, Stämpfli P, Seifritz E, Scheidegger M, Vollenweider FX. Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. Proceedings of the National Academy of Sciences of the United States of America. PMID 27091970 DOI: 10.1073/Pnas.1524187113 |
0.338 |
|
2016 |
Kraehenmann R, Schmidt A, Friston K, Preller KH, Seifritz E, Vollenweider FX. The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. Neuroimage. Clinical. 11: 53-60. PMID 26909323 DOI: 10.1016/J.Nicl.2015.08.009 |
0.332 |
|
2016 |
Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 26875114 DOI: 10.1016/J.Euroneuro.2016.01.005 |
0.412 |
|
2016 |
Preller K, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Staempfli P, Seifritz E, Vollenweider F. The role of the serotonin 2A receptor in the fabric and modulation of personal meaning in lysergic acid diethylamide (LSD)-induced states European Neuropsychopharmacology. 26: S299-S300. DOI: 10.1016/S0924-977X(16)31200-7 |
0.329 |
|
2015 |
Bernasconi F, Kometer M, Pokorny T, Seifritz E, Vollenweider FX. The electrophysiological effects of the serotonin 1A receptor agonist buspirone in emotional face processing. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 25: 474-82. PMID 25637265 DOI: 10.1016/J.Euroneuro.2015.01.009 |
0.321 |
|
2015 |
Preller K, Pokorny T, Krähenmann R, Dziobek I, Stämpfli P, Vollenweider F. The Effect of 5-HT2A/1a Agonist Treatment On Social Cognition, Empathy, and Social Decision-making European Psychiatry. 30: 22. DOI: 10.1016/S0924-9338(15)30017-1 |
0.351 |
|
2014 |
Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Müller F, Borgwardt S, Liechti ME. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. Biological Psychiatry. PMID 25575620 DOI: 10.1016/J.Biopsych.2014.11.015 |
0.366 |
|
2014 |
Ort A, Kometer M, Rohde J, Seifritz E, Vollenweider FX. The role of GABAB receptors in human reinforcement learning. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 1606-14. PMID 25194227 DOI: 10.1016/J.Euroneuro.2014.08.013 |
0.323 |
|
2014 |
Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biological Psychiatry. PMID 24882567 DOI: 10.1016/J.Biopsych.2014.04.010 |
0.347 |
|
2014 |
Csomor PA, Preller KH, Geyer MA, Studerus E, Huber T, Vollenweider FX. Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 39: 2485-96. PMID 24801767 DOI: 10.1038/Npp.2014.102 |
0.5 |
|
2014 |
Bernasconi F, Schmidt A, Pokorny T, Kometer M, Seifritz E, Vollenweider FX. Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin. Cerebral Cortex (New York, N.Y. : 1991). 24: 3221-31. PMID 23861318 DOI: 10.1093/Cercor/Bht178 |
0.334 |
|
2014 |
Kraehenmann R, Preller K, Seifritz E, Vollenweider F. P.1.g.005 Serotonergic modulation of emotion processing by the mixed 5-HT1A/2A receptor agonist psilocybin reduces amygdala activation to negative stimuli – a pharmacological fMRI study European Neuropsychopharmacology. 24: S204-S205. DOI: 10.1016/S0924-977X(14)70316-5 |
0.341 |
|
2013 |
Kometer M, Schmidt A, Jäncke L, Vollenweider FX. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 33: 10544-51. PMID 23785166 DOI: 10.1523/Jneurosci.3007-12.2013 |
0.399 |
|
2013 |
Holstein DH, Vollenweider FX, Geyer MA, Csomor PA, Belser N, Eich D. Sensory and sensorimotor gating in adult attention-deficit/hyperactivity disorder (ADHD). Psychiatry Research. 205: 117-26. PMID 23017654 DOI: 10.1016/J.Psychres.2012.08.013 |
0.468 |
|
2013 |
Schmidt A, Kometer M, Bachmann R, Seifritz E, Vollenweider F. The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology. 225: 227-39. PMID 22836372 DOI: 10.1007/S00213-012-2811-0 |
0.361 |
|
2012 |
Kraehenmann R, Vollenweider FX, Seifritz E, Kometer M. Crowding deficits in the visual periphery of schizophrenia patients. Plos One. 7: e45884. PMID 23049884 DOI: 10.1371/Journal.Pone.0045884 |
0.341 |
|
2012 |
Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biological Psychiatry. 72: 898-906. PMID 22578254 DOI: 10.1016/J.Biopsych.2012.04.005 |
0.338 |
|
2012 |
Schmidt A, Bachmann R, Kometer M, Csomor PA, Stephan KE, Seifritz E, Vollenweider FX. Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 37: 865-75. PMID 22030715 DOI: 10.1038/Npp.2011.261 |
0.415 |
|
2012 |
Quednow BB, Treyer V, Hasler F, Dörig N, Wyss MT, Burger C, Rentsch KM, Westera G, Schubiger PA, Buck A, Vollenweider FX. Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography. Neuroimage. 59: 3922-32. PMID 21996132 DOI: 10.1016/J.Neuroimage.2011.09.045 |
0.353 |
|
2012 |
Quednow BB, Kometer M, Geyer MA, Vollenweider FX. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 37: 630-40. PMID 21956447 DOI: 10.1038/Npp.2011.228 |
0.536 |
|
2011 |
Holstein DH, Csomor PA, Geyer MA, Huber T, Brugger N, Studerus E, Vollenweider FX. The effects of sertindole on sensory gating, sensorimotor gating, and cognition in healthy volunteers. Journal of Psychopharmacology (Oxford, England). 25: 1600-13. PMID 21890590 DOI: 10.1177/0269881111415734 |
0.541 |
|
2011 |
Kometer M, Cahn BR, Andel D, Carter OL, Vollenweider FX. The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biological Psychiatry. 69: 399-406. PMID 21126732 DOI: 10.1016/J.Biopsych.2010.10.002 |
0.734 |
|
2011 |
Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. Journal of Psychopharmacology (Oxford, England). 25: 1434-52. PMID 20855349 DOI: 10.1177/0269881110382466 |
0.341 |
|
2010 |
Holstein DH, Vollenweider FX, Jäncke L, Schopper C, Csomor PA. P50 suppression, prepulse inhibition, and startle reactivity in the same patient cohort suffering from posttraumatic stress disorder. Journal of Affective Disorders. 126: 188-97. PMID 20347156 DOI: 10.1016/J.Jad.2010.02.122 |
0.306 |
|
2010 |
Roser P, Vollenweider FX, Kawohl W. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 11: 208-19. PMID 20218784 DOI: 10.3109/15622970801908047 |
0.391 |
|
2010 |
Hilti CC, Delko T, Orosz AT, Thomann K, Ludewig S, Geyer MA, Vollenweider FX, Feldon J, Cattapan-Ludewig K. Sustained attention and planning deficits but intact attentional set-shifting in neuroleptic-naïve first-episode schizophrenia patients. Neuropsychobiology. 61: 79-86. PMID 20016226 DOI: 10.1159/000265133 |
0.48 |
|
2010 |
Carter OL, Burr DC, Pettigrew JD, Vollenweider FX. Using psilocybin to investigate the relationship between attention, working memory and the serotonin 5-HT1A and 5-HT2A receptors Journal of Vision. 5: 683-683. DOI: 10.1167/5.8.683 |
0.303 |
|
2010 |
Geyer MA, Nichols DE, Vollenweider FX. Serotonin-related psychedelic drugs Encyclopedia of Neuroscience. 731-738. DOI: 10.1016/B978-008045046-9.01160-8 |
0.332 |
|
2009 |
Quednow BB, Schmechtig A, Ettinger U, Petrovsky N, Collier DA, Vollenweider FX, Wagner M, Kumari V. Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: a replication study. Biological Psychiatry. 66: 614-20. PMID 19545856 DOI: 10.1016/J.Biopsych.2009.05.007 |
0.364 |
|
2009 |
Hasler F, Studerus E, Lindner K, Ludewig S, Vollenweider FX. Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. Journal of Psychopharmacology (Oxford, England). 23: 923-35. PMID 18635693 DOI: 10.1177/0269881108094650 |
0.426 |
|
2009 |
Csomor PA, Yee BK, Feldon J, Theodoridou A, Studerus E, Vollenweider FX. Impaired prepulse inhibition and prepulse-elicited reactivity but intact reflex circuit excitability in unmedicated schizophrenia patients: a comparison with healthy subjects and medicated schizophrenia patients. Schizophrenia Bulletin. 35: 244-55. PMID 18245063 DOI: 10.1093/Schbul/Sbm146 |
0.368 |
|
2008 |
Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends in Pharmacological Sciences. 29: 445-53. PMID 19086254 DOI: 10.1016/J.Tips.2008.06.006 |
0.516 |
|
2008 |
Csomor PA, Yee BK, Vollenweider FX, Feldon J, Nicolet T, Quednow BB. On the influence of baseline startle reactivity on the indexation of prepulse inhibition. Behavioral Neuroscience. 122: 885-900. PMID 18729642 DOI: 10.1037/0735-7044.122.4.885 |
0.326 |
|
2008 |
Wackermann J, Wittmann M, Hasler F, Vollenweider FX. Effects of varied doses of psilocybin on time interval reproduction in human subjects. Neuroscience Letters. 435: 51-5. PMID 18325673 DOI: 10.1016/J.Neulet.2008.02.006 |
0.509 |
|
2008 |
Cattapan-Ludewig K, Ludewig S, Messerli N, Vollenweider FX, Seitz A, Feldon J, Paulus MP. Decision-making dysregulation in first-episode schizophrenia. The Journal of Nervous and Mental Disease. 196: 157-60. PMID 18277225 DOI: 10.1097/Nmd.0B013E318162Aa1B |
0.308 |
|
2008 |
Quednow BB, Csomor PA, Chmiel J, Beck T, Vollenweider FX. Sensorimotor gating and attentional set-shifting are improved by the mu-opioid receptor agonist morphine in healthy human volunteers. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 11: 655-69. PMID 18272020 DOI: 10.1017/S1461145707008322 |
0.354 |
|
2008 |
Csomor PA, Stadler RR, Feldon J, Yee BK, Geyer MA, Vollenweider FX. Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 497-512. PMID 17460616 DOI: 10.1038/Sj.Npp.1301421 |
0.526 |
|
2008 |
Vollenweider F, Hell D, Kometer M. Effects of the hallucinogenic 5-HT2A agonist psilocybin on object completion in humans International Journal of Psychophysiology. 69: 157. DOI: 10.1016/J.Ijpsycho.2008.05.397 |
0.302 |
|
2007 |
Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 1876-87. PMID 17299516 DOI: 10.1038/Sj.Npp.1301324 |
0.555 |
|
2007 |
Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX. Effects of psilocybin on time perception and temporal control of behaviour in humans. Journal of Psychopharmacology (Oxford, England). 21: 50-64. PMID 16714323 DOI: 10.1177/0269881106065859 |
0.753 |
|
2006 |
Vollenweider FX, Barro M, Csomor PA, Feldon J. Clozapine enhances prepulse inhibition in healthy humans with low but not with high prepulse inhibition levels. Biological Psychiatry. 60: 597-603. PMID 16997001 DOI: 10.1016/J.Biopsych.2006.03.058 |
0.389 |
|
2005 |
Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. Journal of Cognitive Neuroscience. 17: 1497-508. PMID 16269092 DOI: 10.1162/089892905774597191 |
0.368 |
|
2005 |
Cattapan-Ludewig K, Hilti CC, Ludewig S, Vollenweider FX, Feldon J. Rapid visual information processing in schizophrenic patients: the impact of cognitive load and duration of stimulus presentation. A pilot study. Neuropsychobiology. 52: 130-4. PMID 16110246 DOI: 10.1159/000087558 |
0.338 |
|
2005 |
Csomor PA, Vollenweider FX, Feldon J, Yee BK. On the feasibility to detect and to quantify prepulse-elicited reaction in prepulse inhibition of the acoustic startle reflex in humans. Behavioural Brain Research. 162: 256-63. PMID 15970219 DOI: 10.1016/J.Bbr.2005.03.020 |
0.328 |
|
2005 |
Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, Vollenweider FX. Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 30: 1154-62. PMID 15688092 DOI: 10.1038/Sj.Npp.1300621 |
0.397 |
|
2005 |
Ludewig S, Geyer MA, Ramseier M, Vollenweider FX, Rechsteiner E, Cattapan-Ludewig K. Information-processing deficits and cognitive dysfunction in panic disorder. Journal of Psychiatry & Neuroscience : Jpn. 30: 37-43. PMID 15644996 |
0.357 |
|
2004 |
Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology. 172: 145-56. PMID 14615876 DOI: 10.1007/S00213-003-1640-6 |
0.358 |
|
2003 |
Ludewig K, Paulus MP, Vollenweider FX. Behavioural dysregulation of decision-making in deficit but not nondeficit schizophrenia patients. Psychiatry Research. 119: 293-306. PMID 12914900 DOI: 10.1016/S0165-1781(03)00103-3 |
0.327 |
|
2003 |
Ludewig K, Geyer MA, Vollenweider FX. Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. Biological Psychiatry. 54: 121-8. PMID 12873801 DOI: 10.1016/S0006-3223(02)01925-X |
0.508 |
|
2003 |
Ludewig K, Ludewig S, Seitz A, Obrist M, Geyer MA, Vollenweider FX. The acoustic startle reflex and its modulation: effects of age and gender in humans. Biological Psychology. 63: 311-23. PMID 12853174 DOI: 10.1016/S0301-0511(03)00074-7 |
0.446 |
|
2003 |
Umbricht D, Vollenweider FX, Schmid L, Grübel C, Skrabo A, Huber T, Koller R. Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 170-81. PMID 12496954 DOI: 10.1038/Sj.Npp.1300005 |
0.446 |
|
2003 |
Hasler F, Grimberg U, Benz M, Vollenweider F. P.6.057 Effects of 2A receptor challenge by psilocybin on cognitive performance and neuroendocrine measures in healthy humans: A serotonin model of psychosis European Neuropsychopharmacology. 13: S450. DOI: 10.1016/S0924-977X(03)92355-8 |
0.373 |
|
2003 |
Vollenweider F, Benz M, Etzensberger M, Ludewig K, Hell D. P.2.107 Brain activation patterns during prepulse inhibition (PPI) in first episode schizophrenia and health controls using H2 15O-PET European Neuropsychopharmacology. 13: S327. DOI: 10.1016/S0924-977X(03)92060-8 |
0.304 |
|
2002 |
Vollenweider FX, Liechti ME, Gamma A, Greer G, Geyer M. Acute psychological and neurophysiological effects of MDMA in humans. Journal of Psychoactive Drugs. 34: 171-84. PMID 12691207 DOI: 10.1080/02791072.2002.10399951 |
0.523 |
|
2002 |
Leumann L, Feldon J, Vollenweider FX, Ludewig K. Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia. Biological Psychiatry. 52: 729-39. PMID 12372664 DOI: 10.1016/S0006-3223(02)01344-6 |
0.359 |
|
2002 |
Ludewig K, Vollenweider FX. Impaired sensorimotor gating in schizophrenia with deficit and with nondeficit syndrome. Swiss Medical Weekly. 132: 159-65. PMID 12070788 DOI: 10.4414/Smw.2002.09873 |
0.338 |
|
2002 |
Ludewig K, Geyer MA, Etzensberger M, Vollenweider FX. Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia. Schizophrenia Research. 55: 129-37. PMID 11955972 DOI: 10.1016/S0920-9964(01)00198-0 |
0.502 |
|
2002 |
Umbricht D, Koller R, Vollenweider FX, Schmid L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biological Psychiatry. 51: 400-6. PMID 11904134 DOI: 10.1016/S0006-3223(01)01242-2 |
0.383 |
|
2002 |
Ludewig S, Ludewig K, Geyer MA, Hell D, Vollenweider FX. Prepulse inhibition deficits in patients with panic disorder. Depression and Anxiety. 15: 55-60. PMID 11891993 DOI: 10.1002/Da.10026 |
0.444 |
|
2001 |
Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Human Psychopharmacology. 16: 589-598. PMID 12404538 DOI: 10.1002/Hup.348 |
0.399 |
|
2001 |
Vollenweider FX, Geyer MA. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Research Bulletin. 56: 495-507. PMID 11750795 DOI: 10.1016/S0361-9230(01)00646-3 |
0.534 |
|
2001 |
Leumann L, Sterchi D, Vollenweider F, Ludewig K, Früh H. A neural network approach to the acoustic startle reflex and prepulse inhibition Brain Research Bulletin. 56: 101-110. PMID 11704346 DOI: 10.1016/S0361-9230(01)00607-4 |
0.3 |
|
2001 |
Frei E, Gamma A, Pascual-Marqui R, Lehmann D, Hell D, Vollenweider FX. Localization of MDMA-induced brain activity in healthy volunteers using low resolution brain electromagnetic tomography (LORETA). Human Brain Mapping. 14: 152-65. PMID 11559960 DOI: 10.1002/Hbm.1049 |
0.352 |
|
2001 |
Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology. 154: 161-8. PMID 11314678 DOI: 10.1007/S002130000648 |
0.336 |
|
2001 |
Gamma A, Buck A, Berthold T, Vollenweider FX. No difference in brain activation during cognitive performance between ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: a [H2(15)O]-positron emission tomography study. Journal of Clinical Psychopharmacology. 21: 66-71. PMID 11199950 DOI: 10.1097/00004714-200102000-00012 |
0.308 |
|
2001 |
Liechti ME, Geyer MA, Hell D, Vollenweider FX. Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 24: 240-52. PMID 11166515 DOI: 10.1016/S0893-133X(00)00199-8 |
0.538 |
|
2001 |
Vollenweider F, Bächle D, Ludewig K, Geyer M, Hell D. Brain activation patterns of prepulse inhibition in humans: A [H2 15O]PET study European Neuropsychopharmacology. 11: S359-S360. DOI: 10.1016/S0924-977X(01)80544-7 |
0.414 |
|
2001 |
Liechti M, Gamma A, Vollenweider F. No lasting psycho-physiological effects of a single dose of MDMA (“Ecstasy”) in controlled conditions in healthy human volunteers European Neuropsychopharmacology. 11: S330. DOI: 10.1016/S0924-977X(01)80475-2 |
0.301 |
|
2001 |
Ludewig S, Ludewig K, Geyer M, Hell D, Vollenweider F. Deficient prepulse inhibition of the acoustic startle reflex in panic disorder European Neuropsychopharmacology. 11: S312. DOI: 10.1016/S0924-977X(01)80434-X |
0.414 |
|
2000 |
Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Archives of General Psychiatry. 57: 1139-47. PMID 11115327 DOI: 10.1001/Archpsyc.57.12.1139 |
0.408 |
|
2000 |
Liechti ME, Vollenweider FX. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. Journal of Psychopharmacology (Oxford, England). 14: 269-74. PMID 11106307 DOI: 10.1177/026988110001400313 |
0.351 |
|
2000 |
Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX. Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 23: 396-404. PMID 10989266 DOI: 10.1016/S0893-133X(00)00126-3 |
0.397 |
|
2000 |
Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX, Hell D. 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 23: 388-95. PMID 10989265 DOI: 10.1016/S0893-133X(00)00130-5 |
0.319 |
|
2000 |
Liechti ME, Vollenweider FX. Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 10: 289-95. PMID 10871712 DOI: 10.1016/S0924-977X(00)00086-9 |
0.367 |
|
2000 |
Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 22: 513-21. PMID 10731626 DOI: 10.1016/S0893-133X(99)00148-7 |
0.342 |
|
2000 |
Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. Journal of Psychiatric Research. 34: 35-43. PMID 10696831 DOI: 10.1016/S0022-3956(99)00031-X |
0.36 |
|
2000 |
Vollenweider F, Liechti M, Geyer M, Hell D. S30.02 Effects of MDMA (ecstasy) on sensorimotor gating (prepulse inhibition) in humans after pretreatment with citalopram, haloperidol, or ketanserin European Psychiatry. 15: 273s-273s. DOI: 10.1016/S0924-9338(00)94183-X |
0.395 |
|
2000 |
Umbricht D, Vollenweider F, Schmid L, Koller R. Investigations into the neurobiology of information processing deficits in schizophrenia Schizophrenia Research. 41: 290-291. DOI: 10.1016/S0920-9964(00)91037-5 |
0.319 |
|
2000 |
Schmid L, Koller R, Vollenweider F, Umbricht D. The role of NMDA/glutamate and 5-HT2A/serotonin systems in working memory deficits in schizophrenia Schizophrenia Research. 41: 278. DOI: 10.1016/S0920-9964(00)91003-X |
0.313 |
|
2000 |
Vollenweider F, Umbricht D, Geyer M, Hell D. Effects of NMDA-antagonists and 5-HT2A-agonists on prepulse inhibition in human volunteers Schizophrenia Research. 41: 147. DOI: 10.1016/S0920-9964(00)90657-1 |
0.474 |
|
2000 |
Umbricht D, Vollenweider F, Schmid L, Koller R. How specific are deficits in generation of mismatch negativity to schizophrenia? Schizophrenia Research. 41: 31-32. DOI: 10.1016/S0920-9964(00)90370-0 |
0.313 |
|
2000 |
Ludewig K, Etzensberger M, Geyer M, Vollenweider F. 512. Stability of prepulse inhibition of the acoustic startle reflex in schizophrenia Biological Psychiatry. 47: S155. DOI: 10.1016/S0006-3223(00)00782-4 |
0.461 |
|
2000 |
Liechti M, Geyer M, Hell D, Vollenweider F. 485. MDMA (“ecstasy”) effects on sensorimotor gating after selective pretreatments in humans Biological Psychiatry. 47: S148. DOI: 10.1016/S0006-3223(00)00755-1 |
0.415 |
|
2000 |
Vollenweider F, Bächle D, Leenders K, Missimer J, Hell D. 423. 5-HT2 receptor activation: a common denominator of the NMDA antagonist and 5-HT2A agonist models of psychosis? Biological Psychiatry. 47: S129-S130. DOI: 10.1016/S0006-3223(00)00693-4 |
0.329 |
|
2000 |
Umbricht D, Halder P, Vollenweider F, Schmid L, Koller R. 178. NMDA receptor dysfunction and abnormal information encoding Biological Psychiatry. 47: S54. DOI: 10.1016/S0006-3223(00)00440-6 |
0.389 |
|
2000 |
Umbricht D, Vollenweider F, Schmid L, Koller R. 177. NMDA and 5-HT2A receptor dysfunction in working memory deficits in schizophrenia Biological Psychiatry. 47: S53. DOI: 10.1016/S0006-3223(00)00439-X |
0.33 |
|
1999 |
Vollenweider FX, Remensberger S, Hell D, Geyer MA. Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacology. 143: 365-72. PMID 10367553 DOI: 10.1007/S002130050960 |
0.504 |
|
1999 |
Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 20: 424-33. PMID 10192823 DOI: 10.1016/S0893-133X(98)00108-0 |
0.361 |
|
1999 |
Vollenweider F, Liechti M, Gamma A, Geyer M, Hell D. Opposite effects of 3,4-methylenedioxy-methamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans European Neuropsychopharmacology. 9: 238-239. DOI: 10.1016/S0924-977X(99)80201-6 |
0.368 |
|
1998 |
Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 9: 3897-902. PMID 9875725 DOI: 10.1097/00001756-199812010-00024 |
0.413 |
|
1998 |
Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naïve healthy volunteers. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 19: 241-51. PMID 9718588 DOI: 10.1016/S0893-133X(98)00013-X |
0.354 |
|
1997 |
Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 16: 357-72. PMID 9109107 DOI: 10.1016/S0893-133X(96)00246-1 |
0.322 |
|
1997 |
Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 7: 25-38. PMID 9088882 DOI: 10.1016/S0924-977X(96)00042-9 |
0.345 |
|
1997 |
Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 7: 9-24. PMID 9088881 DOI: 10.1016/S0924-977X(96)00039-9 |
0.322 |
|
Show low-probability matches. |